The global angiography devices market size was valued at USD 9.8 billion in 2018 and is projected to expand at a CAGR of 6.54% over the forecast period. Increasing scope of application and technological innovations are expected to be the key growth-driving factors for the market. Investments in the healthcare sector, increasing geriatric population, and rising prevalence of Cardiovascular Diseases (CVDs) are several other prominent factors responsible for market growth. According to the World Health Organization (WHO), in 2016, more than 75% of the CVD deaths were caused in low-income and middle-income countries due to the lack of easy access to primary health care programs for early detection and treatment.
CVD is the leading cause of death in the U.S. According to the American Heart Association statistical fact sheet 2016, CVD accounted for 43.8% of the total deaths followed by stroke (16.8%), high BP (9.4%), and heart failure (9.0%). More than 130 Million adults in the country are likely to have one or more forms of CVD by 2035.
According to the WHO, factors including tobacco and alcohol consumption, unhealthy diet, obesity, and physical inactivity increase the risk of CVD. The incidence of obesity in adults rose from 34.9% to 37.7% in 2014 and 16.9% to 17.2% in children. Per person, approximately USD 10,348 was spent on healthcare in the country.
Changing regulatory scenario is likely to affect the manufacturers in the U.S. In accordance to the ACA and Health Care and Education Affordability Reconciliation Act, the manufacturers in the country were required to pay 2.3% excise tax on U.S. sales of class I, II, and III medical devices from January 2013.
The global angiography equipment market is segmented into accessories, systems, guidewire, catheters, balloons, vascular closure devices, and contrast media. Angiography systems segment led the market in 2018 due to continuous investments, technological advancements, and growing scope of application. These systems have evolved from catheter-based minimally invasive procedure to digitalized procedures.
Contrast media is expected to be the fastest-growing product segment over the next few years. These products are widely used for enhancing the visibility of blood vessels in imaging techniques, such as CT angiography, MRA, and X-ray. It is also used in projectional radiography and fluoroscopy. Various radiocontrast agents used are iodine, barium-sulphate, and gadolinium.
Based on the technology, the market is segmented into X-ray, MRA, and CT. Companies are investing heavy amounts in the development of new technologies, which is expected to support market growth. Need for reduction of radiation dose, improvement in image quality, and emerging cath lab trends are also expected to drive the market.
MRA is expected to be the fastest-growing technology owing to its advantage of negligible exposure to the radiation in the diagnosis of heart disease. MRA offers 3D capabilities to acquire images in any anatomical plane with excellent soft tissue contrast. The emergence of 3.0T MR imaging has significantly enhanced the diagnosis of coronary artery disease. These factors are also said to boost the segment growth.
According to the procedure, the market is segmented into coronary, endovascular, and neurovascular. Coronary angiography segment dominated the market in 2018. Rising prevalence of Coronary Artery Disease (CAD) and availability of less-invasive imaging modalities are escalating the demand for coronary angiography in developing countries, such as China and India.
Constant developments in the imaging technology have enabled better diagnosis of the disease. The imaging skill has observed changed from single slice CT to multislice CT providing excellent visualization and assessment of CAD. A wide range of options available for diagnosis includes coronary CT angiography,cardiac Magnetic Resonance Imaging (MRI), and cardiac Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET) and integrated SPECT/CT and PET/CT.
Rising awareness about CVDs and associated risk factors are expected to drive the market. Globally, CAD accounts for the maximum number of deaths and disabilities. The joint initiatives of the WHO and state governments to increase the awareness about heart diseases and underlying causes is further expected to contribute to the angiography equipment market growth.
The diagnostic application dominated the market in 2018. Development in CTA and MRA provides appropriate information not only in cardiology but in neurology, such as cerebral aneurysms, acute stroke, brain arteriovenous malformation, dural arteriovenous fistula, suspected cerebral vasculitis, and occlusive diseases.
Asia Pacific is expected to emerge as the fastest-growing region over the forecast period. Favorable reimbursement policies of the Japanese government promoting technological advancements is supporting the region’s growth. The regulatory scenario is not stringent in countries, such as South Korea, Brazil, and India, offering an attractive opportunity for global companies to set their footprints in these markets. China is undergoing consolidation to upgrade the quality of this equipment. Rising import from the largest market players, such as GE Healthcare, Siemens Healthcare, and Koninklijke Philips N.V., is fueling the growth of the China angiography market.
North America led the market in 2018 and is likely to expand further due to increasing geriatric population and prevalence of CVDs. Presence of major companies in the U.S. attributes to the major share of the market. GE Healthcare; Philips Healthcare; Boston Scientific Corporation; Abbott Laboratories; AngioDynamics, Inc.; Cordis Corp.; Carestream Health; and Hologic, Inc. are some of the angiography equipment manufacturing companies based in U.S. Europe is also anticipated to witness significant growth over the coming years due to the presence of majority of local and foreign manufacturers. Growing demand for advanced medical devices and prevalence of CVD are expected to drive the regional market.
Some of key industry participants are Medtronic, Inc.; Abbott Laboratories; GE Healthcare; Boston Scientific Corporation; Koninklijke Philips N.V.; AngioDynamics, Inc.; Shimadzu Corporation; Cordis Corporation; B. Braun Melsungen AG; and Siemens Healthcare Ltd. Most of these companies are investing in R&D to increase their product portfolio. For instance, in 2018, Shimadzu Corp. released three models of Trinias and minimally invasive Bi-plane angiography system. Also, in 2017, Medtronic Inc. introduced DxTerity Diagnostic Angiography Catheter line to the existing catheter range.
Base year for estimation
Actual estimates/Historical data
2015 - 2018
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, and MEA
U.S., Canada, U.K., Germany, France, Japan, China, India, Brazil, Mexico, and South Africa
Revenue forecast, company share, competitive landscape, growth factors & trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global angiography devices market report on the basis of product, technology, procedure, application, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Vascular closure devices
Technology Outlook (Revenue, USD Million, 2015 - 2026)
Procedure Outlook (Revenue, USD Million, 2015 - 2026)
Application Outlook (Revenue, USD Million, 2015 - 2026)
Regional Outlook (Revenue, USD Million, 2015 - 2026)
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.